The dynamics of an epidemic model with targeted antiviral prophylaxis

Journal of Biological Dynamics

Volumn 4, Issue 5, 2010, Pages 506-526

  Qiu, Zhipeng ^a   Feng, Zhilan ^b  

^a NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Bi stability; Bifurcation; Epidemic model; Reproduction number; Targeted prophylaxis

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; BASIC REPRODUCTION NUMBER; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; COMPUTER SIMULATION; DISEASE TRANSMISSION; ENDEMIC DISEASE; EPIDEMIC; HUMAN; INFECTION CONTROL; TIME; VIROLOGY;

ANTIVIRAL AGENTS; BASIC REPRODUCTION NUMBER; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COMPUTER SIMULATION; ENDEMIC DISEASES; EPIDEMICS; HUMANS; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 79960505815     PISSN: 17513758     EISSN: 17513766     Source Type: Journal    
DOI: 10.1080/17513758.2010.498925     Document Type: Article

References (26)

1. M.E. Alexander and S.M. Moghadas, Bifurcation analysis of an SIRS epidemic model with generalized incidence, SIAM J. Appl. Math. 65 (2005), pp. 1794-1816.
2. M.E. Alexander, S.M. Moghadas, G. Röst, and J. Wu, A delay differential model for pandemic influenza with antiviral treatment, Bull. Math. Biol. 70 (2008), pp. 382-397.
3. M.E. Alexander, C.S. Bowman, S.M. Moghadas, R. Summers, A.B. Gumel, and B.M. Sahai, A vaccination model for transmission dynamics of influenza, SIAM J. Appl. Dyn. Syst. 3 (2004), pp. 503-524.
4. M.E. Alexander, C.S. Bowman, Z. Feng, M. Gardam, S.M. Moghadas, G. Röst, J. Wu, and P. Yan, Emergence of drug resistance: Implications for antiviral control of pandemic influenza, Proc. R. Soc. B 274 (2007), pp. 1675-1684.
5. J. Arino, C.C. Mccluskey, and P. van Den Driessche, Global results for an epidemic model with vaccination that exhibits backward bifurcation, SIAM J. Appl. Math. 64 (2003), pp. 260-276.
6. J. Dushoff, W. Huang, and C. Castillo-Chavez, Backwards bifurcations and catastrophe in simple models of fatal diseases, J. Math. Biol. 36 (1998), pp. 227-248.
7. Z.L. Feng, C. Castillo-Chavez, and A.F. Capurro, A model for tuberculosis with exogenous reinfection, Theor. Popul. Biol. 57 (2000), pp. 235-247.
8. N.M. Ferguson, S. Mallett, H. Jackson, N. Roberts, and P. Ward, A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals, J. Anti. Chemo. 51 (2003), pp. 977-990.
9. N.M. Ferguson, D.A.T. Cummings, C. Fraser, J.C. Cajka, P.C. Cooley, and D.S. Burke, Strategies for mitigating an influenza pandemic, Nature 442 (2006), pp. 448-452.
10. R. Gani, H. Hughes, D. Fleming, T. Griffin, J. Medlock, and S. Leach, Potential impact of antiviral drug use during influenza pandemic, Emerg. Infect. Dis. 11 (2005), pp. 1355-1362.
11. K.P. Hadeler and C. Castillo-Chavez, A core group model for disease transmission, Math. Biosci. 128 (1995), pp. 41-55.
12. F.G. Hayden and F.Y. Aoki, Amantadine, rimantadine, and relate agents, in Antimicrobial Therapy and Vaccines, V.Yu, T. Meigan, and S. Barriere, eds.,Williams andWilkins, Baltimore, MD, 1999, pp. 1344-1365.
13. J.F. Jiang and Z.P. Qiu, The complete classification for dynamics in a nine-dimensionalWest Nile virus model, SIAM J. Appl. Math. 69 (2009), pp. 1205-1227.
14. [J.F. Jiang, Z.P. Qiu, J.H. Wu, and H.P. Zhu, Threshold conditions for West Nile virus outbreaks, Bull. Math. Biol.71 (2009), pp. 627-647.
15. Y.A. Kuznetsov, Elements of Applied Bifurcation Theory, Springer-Verlag, NewYork, 1995.
16. M. Lipsitch, T. Cohen, M. Murray, and B.R. Levin, Antiviral resistance and the control of pandemic influenza, PLoS Med. 4 (2007), pp. 0111-0120.
17. W.M. Liu, Criterion of Hopf bifurcation without using enigenvalues, J. Math. Anal. Appl. 182 (1994), pp. 250-256.
18. I.M. Longini, Jr., M.E. Halloran, A. Nizam, and Y. Yang, Containing pandemic influenza with antiviral agents, Am. J. Epidemiol. 159 (2004), pp. 623-633.
19. I.M. Longini, Jr., A. Nizanm, S. Xu, K. Ungchusak, W. Hanshaoworakul, D.A.T. Cummings, and M.E. Halloran, Containing pandemic influenza at the source, Science 309 (2005), pp. 1083-1087.
20. J.M. McCaw and J. McVernon, Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic, Math. Biosci. 209 (2007), pp. 336-360.
21. [J.M. McCaw, J.G. Wood, C.T. McCaw, and J. McVernon, Impact of emerging antiviral drug resistance on influenza containment and spread: Influence of subclinical infection and strategic use of a stockpile containing one or two drugs, PLoS ONE, 3 (2008), p. e2362, doi:10.1371/journal.pone.0002362.
22. [S. Merler, M. Ajelli, and C. Rizzo, Age-priortized use of antirvirals during an influenza pandemic,. BMC Infect Dis. 9 (2009), p. 117.
23. Z.P. Qiu and Z.L. Feng, Transmission dynamics of an influenza model with vaccination and antiviral treatment, Bull. Math. Biol. 72 (2009), pp. 1-33.
24. H.R. Thieme, A. Tridane, and Y. Kuang, An epidemic model with post-contact prophylaxis of distributed length. I. Thresholds for disease persistence and extinction, J. Biol. Dyn. 2 (2008), pp. 221-239.
25. H.R. Thieme, A. Tridane, and Y. Kuang, An epidemic model with post-contact prophylaxis of distributed length. II. Stability and oscillations if treatment is fully effective, Math. Mod. Nat. Phenom. 3 (2008), pp. 267-293.
26. J. Treanor, Influenza vaccine-outmaneuvering antigenic shift and drift, N. Engl. J. Med. 350 (2004), pp. 218-220.